Back to top

Image: Bigstock

Masimo Corporation

Read MoreHide Full Article

Masimo’s third quarter 2015 results were impressive. Top-line growth was driven by new contract wins and strong licensing revenue growth. The company’s innovative product portfolio is a key growth catalyst, in our view. Wider adoption of non-invasive patient monitoring technology will help the company gain market traction. Masimo’s SET pulse oximetry business represents considerable growth opportunities in international markets. Additionally, the announcement of a new share buy-back program is expected to draw investor attention, going forward. However, an unfavorable foreign exchange rate has been a headwind for several quarters and is expected to prevail in the near term as well.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Masimo Corporation (MASI) - free report >>

Published in